Response to Ipilimumab/Nivolumab Rechallenge and BRAF Inhibitor/MEK Inhibitor Rechallenge in a Patient with Advanced Metastatic Melanoma Previously Treated with BRAF Targeted Therapy and Immunotherapy

<div>(a) PET/CT scan prior to start of dabrafenib/trametinib combination therapy showing multiple subcutaneous metastases. (b) PET/CT scan 4 months after initiation of BRAFi/MEKi therapy showing resolution of previously noted subcutaneous metastasis.</div>

Case Reports in Oncological Medicine

fig1

Figure 1

Figure 1: Response to Ipilimumab/Nivolumab Rechallenge and BRAF Inhibitor/MEK Inhibitor Rechallenge in a Patient with Advanced Metastatic Melanoma Previously Treated with BRAF Targeted Therapy and Immunotherapy 

Figure 1 | Response to Ipilimumab/Nivolumab Rechallenge and BRAF Inhibitor/MEK Inhibitor Rechallenge in a Patient with Advanced Metastatic Melanoma Previously Treated with BRAF Targeted Therapy and Immunotherapy 